Crispr Therapeutics Ag Earnings

Crispr Therapeutics Ag’s revenue jumped 47.67% since last year same period to $0.89Mn in the Q3 2025. On a quarterly growth basis, Crispr Therapeutics Ag has generated -0.34% fall in its revenue since last 3-months.

Crispr Therapeutics Ag’s net profit fell -23.85% since last year same period to $-106.44Mn in the Q3 2025. On a quarterly growth basis, Crispr Therapeutics Ag has generated 48.96% jump in its net profits since last 3-months.

Crispr Therapeutics Ag’s net profit margin jumped 16.13% since last year same period to -11973.12% in the Q3 2025. On a quarterly growth basis, Crispr Therapeutics Ag has generated 48.79% jump in its net profit margins since last 3-months.

Crispr Therapeutics Ag’s earning per share (EPS) estimates for the current quarter stand at -1.1 - a 6.78% jump from last quarter’s estimates.

Crispr Therapeutics Ag’s earning per share (EPS) estimates for the current year stand at -1.1.

Crispr Therapeutics Ag’s earning per share (EPS) jumped 100% since last year same period to 0 in the Q1 2026. This indicates that the Crispr Therapeutics Ag has generated 100% annual rate of jump in its earning per share (EPS) in the last 4 quarters.